Neutrophil cell

To decrease the incidence of chemotherapy-induced myelosuppression in patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen

For extensive-stage small cell lung cancer (ES-SCLC)

SIGNIFICANT REDUCTION OF SEVERE NEUTROPENIA

Pivotal STUDY PRIMARY ENDPOINT: COSELA™ (trilaciclib) Given Prior to Etoposide, Carboplatin, and Atezolizumab (E/P/A) in 1st-Line ES-SCLC Patients

See Study Design

Helped Prevent severe neutropenia in ES-SCLC patients

Graph illustrating how COSELA helped prevent severe neutropenia in ES-SCLC in the Pivotal StudyPROPORTION OF PATIENTS (%)49.1%1.9%E/P/A REGIMEN0%10%20%30%40%50%E/P/A REGIMEN WITH COSELA(N=53)(N=54)REDUCTION96%*

*P<0.0001. Adjusted relative risk 0.038 (95% CI, 0.008, 0.195).

Reduced the duration OF SEVERE NEUTROPENIA in cycle 1

Graph illustrating how COSELA helped reduce the duration of severe neutropenia in cycle 1 in ES-SCLC patients in the Pivotal StudyDAYS (MEAN) IN CYCLE 1 01234E/P/A REGIMEN0 DAYSE/P/A REGIMEN WITH COSELA4 DAYS(N=53)(N=54)

P<0.0001. Mean difference -3.6 (95% CI, -4.9, -2.3). Standard deviation (COSELA: 1 day; E/P/A Regimen Arm: 4.7 days).

E/P/A Regimen Arm = Placebo + E/P/A. Patients in both arms could receive supportive care as described in the study design.

In the Pivotal Study, a G-CSF was administered to 47.2% of patients in the Placebo Group and 29.6% in the COSELA Group at least one time.

COSELA offers a proactive approach to reduce chemotherapy-induced myelosuppression in patients with ES-SCLC

INCIDENCE AND DURATION OF SEVERE NEUTROPENIA IN STUDY 2

STUDY 2 ENDPOINTS: COSELA Given Prior to Etoposide and Carboplatin (E/P) in 1st-Line ES-SCLC Patients

See Study Design

Incidence of Severe Neutropenia DURING STUDY

Graph illustrating incidence of severe neutropenia in ES-SCLC patients during study 2PROPORTION OF PATIENTS (%)42%5%(N=38)(N=39)E/P REGIMENE/P REGIMEN WITH COSELA0%10%20%30%40%50%

Duration of Severe Neutropenia in cycle 1

Graph illustrating duration of severe neutropenia in ES-SCLC patients in Cycle 1 in Study 20 DAYS3 DAYSE/P REGIMENE/P REGIMEN WITH COSELADAYS (MEAN) IN CYCLE 1 01234(N=38)(N=39)

E/P Regimen Arm = E/P + Placebo. Supportive care was allowed as described in the Pivotal Study.

In Study 2, a G-CSF was administered to 63.2% of patients in the Placebo Group and 10.3% in the COSELA Group at least one time.

INCIDENCE AND DURATION OF SEVERE NEUTROPENIA IN STUDY 3

STUDY 3 ENDPOINTS: COSELA Given Prior to Topotecan in 2nd- and 3rd-Line ES-SCLC Patients

See Study Design

Incidence of Severe Neutropenia DURING STUDY

Graph illustrating incidence of severe neutropenia in ES-SCLC patients during study 3PROPORTION OF PATIENTS (%)76%41%(N=29)(N=32)TOPOTECAN REGIMENTOPOTECAN REGIMEN WITH COSELA0%10%20%30%40%50%60%70%80%

Duration of Severe Neutropenia in cycle 1

Graph illustrating duration of severe neutropenia in ES-SCLC patients in Cycle 1 in Study 3012345672 DAYS7 DAYSTOPOTECAN REGIMENTOPOTECAN REGIMEN WITH COSELA(N=29)(N=32)DAYS (MEAN) IN CYCLE 1

Topotecan Regimen Arm = Topotecan + Placebo. Supportive care was allowed as described in the Pivotal Study.

In Study 3, G-CSF was administered to 65.5% of patients in the Placebo Group and 50.0% in the COSELA Group at least one time.

INDICATION: COSELA is indicated to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive-stage small cell lung cancer (ES-SCLC).